News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
517,579 Results
Type
Article (12209)
Company Profile (142)
Press Release (505226)
Multimedia
Podcasts (31)
Webinars (9)
Section
Business (175447)
Career Advice (374)
Deals (27030)
Drug Delivery (38)
Drug Development (57542)
Employer Resources (20)
FDA (10860)
Job Trends (9397)
News (253985)
Policy (21857)
Tag
2027 Bio NC Standard (1)
2027 Biotech Bay Elite (3)
2027 Biotech Bay Standard (4)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Elite (1)
2027 Pharm Country Standard (1)
Academia (688)
Accelerated approval (27)
ADA (21)
Adcomms (9)
Allergies (112)
Alliances (35320)
ALS (127)
Alzheimer's disease (1050)
Antibody-drug conjugate (ADC) (344)
Approvals (11530)
Artificial intelligence (368)
ASCO (198)
Autoimmune disease (225)
Automation (32)
Bankruptcy (277)
Best Places to Work (7562)
BIO (38)
Biologics (2)
BIOSECURE Act (3)
Biosimilars (150)
BioSpace Insights (26)
Biotechnology (92)
Bladder cancer (162)
Brain cancer (46)
Breast cancer (589)
Cancer (4164)
Cardiovascular disease (272)
Career advice (318)
Career pathing (6)
CAR-T (189)
CDC (5)
Celiac Disease (1)
Cell therapy (532)
Cervical cancer (36)
Clinical research (51667)
Collaboration (1364)
Commercialization (3)
Compensation (1474)
Complete response letters (41)
COVID-19 (1315)
CRISPR (70)
C-suite (817)
Cystic fibrosis (94)
Data (6034)
Decentralized trials (1)
Denatured (5)
Depression (107)
Dermatology (66)
Diabetes (383)
Diagnostics (4456)
Digital health (43)
Diversity (2)
Diversity, equity & inclusion (5)
Drug discovery (185)
Drug pricing (84)
Drug shortages (6)
Duchenne muscular dystrophy (187)
Earnings (76695)
Editorial (9)
Employer branding (5)
Employer resources (23)
Events (91503)
Executive appointments (761)
FDA (13729)
Fibrodysplasia Ossificans Progressiva (10)
Friedreich's ataxia (20)
Frontotemporal dementia (24)
Funding (1028)
Gene editing (139)
Generative AI (16)
Gene therapy (351)
GLP-1 (431)
Government (2514)
Grass and pollen (3)
Guidances (304)
Healthcare (10504)
Hematology (103)
HIV (57)
Huntington's disease (25)
IgA nephropathy (68)
Immunology and inflammation (126)
Immuno-oncology (69)
Indications (167)
Infectious disease (1531)
Inflammatory bowel disease (136)
Inflation Reduction Act (8)
Influenza (88)
Intellectual property (263)
Interviews (47)
IPO (12890)
IRA (26)
Job creations (2242)
Job search strategy (301)
JPM (7)
Kidney cancer (22)
Labor market (4)
Layoffs (106)
Leadership (4)
Legal (5648)
Licensing (10)
Liver cancer (61)
Longevity (18)
Lung cancer (615)
Lymphoma (295)
Machine learning (31)
Management (6)
Manufacturing (628)
Marketing (8)
MASH (119)
Medical device (9325)
Medtech (9478)
Mergers & acquisitions (15186)
Metabolic disorders (817)
mRNA (81)
Multiple sclerosis (109)
NASH (4)
Neurodegenerative disease (240)
Neuropsychiatric disorders (45)
Neuroscience (1982)
NextGen: Class of 2026 (3390)
Non-profit (1267)
Now hiring (3)
Obesity (289)
Opinion (53)
Ovarian cancer (179)
Pain (186)
Pancreatic cancer (211)
Parkinson's disease (212)
Partnered (12)
Patents (519)
Patient recruitment (547)
Peanut (39)
People (43585)
Pharmaceutical (32)
Pharmacy benefit managers (9)
Phase 1 (16305)
Phase 2 (22715)
Phase 3 (16437)
Pipeline (7887)
Policy (90)
Postmarket research (1791)
Preclinical (6804)
Press Release (38)
Prostate cancer (221)
Psychedelics (15)
Radiopharmaceuticals (237)
Rare diseases (643)
Real estate (3305)
Recruiting (11)
Regulatory (17273)
Reports (25)
Research institute (771)
Resumes & cover letters (48)
Rett syndrome (41)
RNA editing (6)
RSV (58)
Schizophrenia (117)
Series A (169)
Series B (129)
Service/supplier (6)
Sickle cell disease (67)
Special edition (5)
Spinal muscular atrophy (93)
Sponsored (9)
Startups (2179)
Stomach cancer (8)
Supply chain (61)
Tariffs (37)
The Weekly (25)
Vaccines (516)
Venture capital (27)
Weight loss (133)
Women's health (87)
Worklife (2)
Date
Today (10)
Last 7 days (231)
Last 30 days (1673)
Last 365 days (20405)
2026 (13256)
2025 (20626)
2024 (24536)
2023 (28200)
2022 (37501)
2021 (40747)
2020 (36832)
2019 (26073)
2018 (19668)
2017 (20473)
2016 (19648)
2015 (25845)
2014 (22715)
2013 (18960)
2012 (20992)
2011 (21207)
2010 (21057)
Location
Africa (317)
Alabama (74)
Alaska (3)
Arizona (312)
Arkansas (11)
Asia (20405)
Australia (2686)
California (12098)
Canada (3709)
China (678)
Colorado (493)
Connecticut (423)
Delaware (286)
Europe (33047)
Florida (1818)
Georgia (382)
Hawaii (3)
Idaho (49)
Illinois (736)
India (65)
Indiana (380)
Iowa (20)
Japan (427)
Kansas (101)
Kentucky (30)
Louisiana (28)
Maine (28)
Maryland (1309)
Massachusetts (8073)
Michigan (308)
Minnesota (573)
Mississippi (4)
Missouri (99)
Montana (21)
Nebraska (13)
Nevada (118)
New Hampshire (65)
New Jersey (2895)
New Mexico (12)
New York (2892)
North Carolina (1321)
North Dakota (4)
Northern California (6078)
Ohio (304)
Oklahoma (14)
Oregon (20)
Pennsylvania (2335)
Puerto Rico (20)
Rhode Island (30)
South America (506)
South Carolina (76)
South Dakota (1)
Southern California (5002)
Tennessee (126)
Texas (2007)
United States (40158)
Utah (362)
Vermont (2)
Virginia (161)
Washington D.C. (44)
Washington State (940)
West Virginia (1)
Wisconsin (74)
Wyoming (1)
517,579 Results for "astrazeneca canada inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Wainua flop narrows AstraZeneca’s path to $80B goal ahead of high-risk readouts
With a Phase 3 failure denting the rare disease drug’s prospects, AstraZeneca has little room for error as it plots a path toward its ambitious 2030 sales target.
July 22, 2026
·
4 min read
·
Nick Paul Taylor
Manufacturing
AstraZeneca partners with CSPC to build Chinese biologics manufacturing plant
News of the joint venture comes months after AstraZeneca vowed to spend $15 billion in China by the end of the decade.
August 10, 2026
·
2 min read
·
Nick Paul Taylor
Lung cancer
AstraZeneca pulls plug on late-stage lung cancer trial, taking another clinical blow
AstraZeneca will push through with its other Phase 3 studies for volrustomig, including in cervical cancer and mesothelioma.
August 17, 2026
·
2 min read
·
Tristan Manalac
Breast cancer
AstraZeneca’s breast cancer pill hit with review delay after negative adcomm vote
An FDA advisory committee recently voted against approving AstraZeneca’s oral SERD drug camizestrant for certain patients with advanced breast cancer. It is unclear when the new target action date for the drug will be.
May 27, 2026
·
4 min read
·
Tristan Manalac
M&A
No deal between AstraZeneca and BMS, senior source insists:
Reuters
Reuters
has deflated rumors that AstraZeneca and Bristol Myers Squibb are discussing a possible merger, letting the air out of industry-wide speculation over what could have been the largest deal in pharma history.
August 5, 2026
·
1 min read
·
Gabrielle Masson
Mergers & acquisitions
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
August 3, 2026
·
3 min read
·
Annalee Armstrong
Business
As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be more mixed.
August 4, 2026
·
3 min read
·
Gabrielle Masson
Cancer
Pathos inks back-to-back cancer contracts with AstraZeneca, China’s Alphamab
Pathos AI could pay more than $2 billion to a Jiangsu Alphamab Biopharmaceuticals subsidiary for a late-stage bispecific antibody-drug conjugate for breast cancer, while the financial details of the AstraZeneca agreement were not disclosed.
August 4, 2026
·
2 min read
·
Tristan Manalac
Immunology and inflammation
AstraZeneca bets up to $1.9B in respiratory disease collab with Sino Biopharmaceutical
In AstraZeneca’s third trip to Asia this year, the pharma secured ex-China rights to a dual inhibitor of PDE3 and PDE4, which in a Phase 2b study significantly improved lung function and lowered symptom burden in patients with chronic obstructive pulmonary disorder.
July 8, 2026
·
2 min read
·
Tristan Manalac
Cardiovascular disease
AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space
The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics.
July 10, 2026
·
3 min read
·
Tristan Manalac
1 of 51,758
Next
